GLP-1 news, explained with dates and prices
Each explainer gives the key numbers first, links the primary source (the drugmaker, FDA or CMS), shows today's cash prices from our dated records and lists what happens next. Outcomes that have not happened yet are written as expected dates.
Announced · Updated Nov 20, 2026
Retatrutide Phase 3 Results: 28.3% Weight Loss at 80 Weeks (Nov 2026)
Lilly's retatrutide produced up to 28.3% average weight loss at 80 weeks in TRIUMPH-1. It is not FDA-approved; Lilly plans to submit it in Q1 2027. What it means for what you pay today.
Announced · Updated Nov 20, 2026
Medicare GLP-1 Bridge: $50 a Month Copay Through 2027 (Nov 2026)
Since July 1, 2026, CMS's Medicare GLP-1 Bridge gives eligible Part D members Wegovy, Foundayo or Zepbound KwikPen for a $50 monthly copay, through December 31, 2027. Who qualifies and what it means for cost.
Announced · Updated Nov 20, 2026
Saxenda Discontinued: Last US Shipments in Late January 2027 (Nov 2026)
Novo Nordisk is discontinuing Saxenda (liraglutide) in the US, with last wholesaler shipments in late January 2027. Why, what happens next and what the alternatives cost today.
Decision pending · Updated Nov 20, 2026
CagriSema FDA Decision: Expected Q4 2026, 20.4% Weight Loss (Nov 2026)
Novo Nordisk filed CagriSema with the FDA in December 2025 and expects a US decision in Q4 2026. As of November 20, 2026 it is not approved. The trial numbers, the dates and what you pay today.



